前收市價 | 88.61 |
開市 | 88.34 |
買盤 | 87.97 x 300 |
賣出價 | 88.22 x 300 |
今日波幅 | 87.93 - 88.65 |
52 週波幅 | 76.02 - 100.38 |
成交量 | |
平均成交量 | 1,325,206 |
市值 | 16.62B |
Beta 值 (5 年,每月) | 0.31 |
市盈率 (最近 12 個月) | 101.25 |
每股盈利 (最近 12 個月) | 0.87 |
業績公佈日 | 2024年4月24日 - 2024年4月29日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 109.48 |
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, the therapy maker said in a filing on Monday. The DOJ has asked the company to submit certain documents related to the sponsored testing of its therapies Vimizim and Naglazyme, BioMarin said. "We have produced documents in response to the subpoena and are cooperating fully, but there is no assurance that such sponsored testing programs, or our other operations or programs, will not be found to violate such laws," the company said in the filing.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript February 22, 2024 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $0.18 EPS, expectations were $0.44. BMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]